

ISSUE OF SPECIFIC  
SCANNED

SERIAL NUMBER 108/960,557	FILING DATE 10/31/97	CLASS 424	SUBCLASS 464	GROUP ART. UNIT 21615	EXAMINER SIGNATURE <i>[Signature]</i>
------------------------------	-------------------------	--------------	-----------------	--------------------------	--

APPLICANT  
EUGENIO A. CEFALI, LAUDERHILL, FL

CONTINUING DATA  
VERIFIED THIS APPLN IS A CIP OF 08/814,974 03/06/97

FOREIGN APPLICATIONS  
VERIFIED

AVAILABLE COPY

BEST AVAILABLE COPY

FOREIGN FILING LICENSE GRANTED 02/18/98.

Foreign priority claimed 35 USC 119 conditions met	<input type="checkbox"/> yes <input checked="" type="checkbox"/> no	AS FILED →	STATE OR COUNTRY FL	SHEETS DRWGS. 5	TOTAL CLAIMS 27	INDEP. CLAIMS 2	FILING FEE RECEIVED \$17.00	ATTORNEY'S DOCKET NO. 3289-1
---	---	---------------	------------------------	--------------------	--------------------	--------------------	--------------------------------	---------------------------------

Verified and Acknowledged Examiner's Initials

PETER JAHNISCH  
ENKEMI TECHNOLOGY  
1111 POST AVENUE  
WHITE ROCK  
DALLAS TX 75201

*Spelman, Senterfield & Associates  
Las Olas Office Suite 700  
450 Las Olas Boulevard  
Fort Lauderdale, FL 33301-2223*

METHODS FOR TREATING HYPERLIPIDEMIA WITH INTERMEDIATE RELEASE NICOTINIC ACID COMPOSITIONS HAVING UNIQUE BIOPHARMACEUTICAL CHARACTERISTICS

U.S. DEPT. OF COMM / PAT & TM PTO-438L (Rev. 12-94)

PARTS OF APPLICATION  
FILED SEPARATELY

Applications Examiner

NOTICE OF ALLOWANCE MAILED

CLAIMS ALLOWED

Total Claims

1st Claim

ISSUE FEE

Amount Due  
Date Paid

DRAWING

Sheets Drwg. Figs. Drwg. Drawn

Label  
Area

Primary Examiner

ISSUE  
BATCH  
NUMBER

PREPARED FOR ISSUE  
WARNING: The information disclosed herein may be restricted. Unauthorized disclosure may be prohibited by the United States Code Title 35 Sections 122-181 and 505. Possession outside the U.S. Patent & Trademark Office is restricted to authorized employees and contractors only.

Form PTO-36A  
(Rev. 3-92)

SCANNED  
OC

(FACE)